Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 7/20 | 0.38 |
| ▸ | RET | P07949 | 7/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | F2R | P25116 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14730345 | 0.90 | NTRK1 (0.40) | NTRK1RETMCHR1 | |
| SCHEMBL14730294 | 0.85 | NTRK1 (0.42) | NTRK1RETMCHR1F2RNPY5R | |
| SCHEMBL14723500 | 0.85 | NTRK1 (0.42) | NTRK1RETMCHR1F2RNPY5R | |
| SCHEMBL14730278 | 0.84 | NTRK1 (0.43) | NTRK1RETMCHR1F2R | |
| SCHEMBL14722263 | 0.84 | NTRK1 (0.43) | NTRK1RETMCHR1F2R | |
| SCHEMBL14730347 | 0.83 | NTRK1 (0.36) | NTRK1MCHR1F2RHDAC3HDAC2 | |
| SCHEMBL1720753 | 0.82 | NTRK1 (0.40) | NTRK1RETMCHR1F2RNPY5R | |
| SCHEMBL609468 | 0.82 | NTRK1 (0.40) | NTRK1RETMCHR1F2RNPY5R | |
| SCHEMBL10058396 | 0.82 | NTRK1 (0.40) | NTRK1RETMCHR1F2RNPY5R | |
| SCHEMBL609745 | 0.79 | RET (0.44) | NTRK1RETMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013026587-A1 | 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |